MET and lung carcinoma: In lung cancer, hepatocyte growth factor induces gefitinib resistance via repressing miR-1-3p expression in PC-9 and HCC827 cells, whereas miR-1-3p restoration abolishes the drug resistance by inhibiting c-Met signaling (Jiao et al., 2018).